Monoclonal Antibodies Market Size, Share | Industry Aalysis 2028

Free Sample PDF Inquiry Before Buying
Biotechnology Monoclonal Antibodies Market

Monoclonal Antibodies Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Source (Human, Humanized, Chimeric, and Murine), Production Method (In-Vitro and In-Vivo), Indication (Cancer, Autoimmune Diseases, Infectious Diseases, Inflammatory Diseases, Microbial Diseases, and Others), Application (Therapeutic Applications, Diagnostic Applications, and Research Applications), and End-User (Hospitals, Others, and Research Institutes)

Publication Month: Jan 2022 | Report Code: TIPRE00026641 | No. of Pages: 163 | Category: Biotechnology | Status: Published

The monoclonal antibodies market is projected to reach US$ 243.05 billion by 2028 from US$ 111.01 billion in 2021; it is expected to grow at a CAGR of 11.8% from 2021 to 2028.

The increasing prevalence of cancer and other chronic diseases, and a tremendous rise in COVID-19 cases across various regions are the key factors fueling the market growth. According to World Cancer Research Fund and American Institute for Cancer, in 2020, ~18.1 million cancer cases were recorded, including 9.3 million cases in men and 8.8 million cases in women. The use of monoclonal antibodies in the treatment of various types of cancer is still in phases 2 and phase 3 trials.

Strategic Insights


North America is likely to continue its dominance in the monoclonal antibodies market during 2021–2028. The US holds the largest share of the market in this region and is expected to continue to be a dominant shareholder in the market during the forecast period. According to the statistics released by Globocan 2020, ~1,806,590 new cases of cancer were diagnosed in the US and ~606,520 people died due to this disease. As per a report by the US Department of Commerce, its National Institute of Standards and Technology (NIST) announced the funding of US$ 153 million to the National Institute for Innovation in Manufacturing Biopharmaceuticals. Additionally, the FDA has been extending support for the development of monoclonal antibodies during COVID-19 prevalence.

Lucrative Regions for monoclonal antibodies Market


Lucrative Regions for monoclonal antibodies Market

Get more information on this report :

Market Insights

Significant Rise in Prevalence of Cancer and Other Chronic Diseases Drives Market Growth

As per the American Cancer Society report, ~16.9 million individuals with a history of cancer were residing in the US as of January 2019. By January 2030, the population of cancer survivors is estimated to rise to 22.1 million due to the growth and aging of the population alone. Therefore, with the growing prevalence of cancer and other chronic diseases, the demand for biologics, such as monoclonal antibodies (mABs), has also surged. Being principal components of many therapeutic regimens and cost-effectiveness treatments, biologics play a key role in cancer treatment.

Source-Based Insights

Based on the source, the monoclonal antibodies market is segmented into murine, chimeric, human, and humanized. The human segment is estimated to account for the largest market share during 2021–2028. The market growth of this segment is attributed to the rise on account of the integration of human monoclonal antibodies for the treatment of various kinds of infectious diseases. For instance, Regeneron launched FDA approved antibody cocktail casirivimab and imdevimab together for use in COVID-19. The drug has received Emergency Use Authorization (EUA) from FDA. It is used for the treatment of mild to moderate COVID-19 in adults as well as in pediatric patients at least 12 years of age and weighing at least 40kg. Moreover, an increase in their use in various chronic diseases and employment of advanced genetic engineering technology are among the significant factors driving the market segment's growth.

Monoclonal antibodies Market, by Source - 2020 and 2028

Get more information on this report :

Indication-Based Insights

Based on indication, cancer, autoimmune diseases, inflammatory diseases, infectious disease, microbial disease, and others. The cancer segment would dominate the market in the coming years. Advancements related to the therapeutic application of monoclonal antibodies have enabled their successful implementation in the treatments of various cancer types, such as breast cancer, lung cancer, and colon cancer. Drugs based on these antibodies help in flagging cancer cells, triggering cell-membrane destruction, blocking immune system inhibitors, and so on. The FDA, in June 2020, approved two drugs—olaparib and rucaparib for the treatment of prostate cancer. The drug is especially effective among men with prostate cancer conditions that have spread or metastasized and has stopped responding to standard hormone treatments, i.e., castration-resistant disease condition.

End-User-Based Insights

By end-user, the monoclonal antibody market is segmented into hospitals, research institutes, and others. The hospital segment holds the largest market share owing to the increasing adoption mABs as a preferred line of treatment, especially for cancer treatment.

Companies operating in the monoclonal antibodies market adopt the product innovation strategy to meet the evolving customer demands across the world, which also permits them to maintain their brand name in the global market.

Monoclonal antibodies Market - Segmentation

Based on the source, the monoclonal antibodies market is segmented into human, humanized, chimeric, and murine. By production method, the market is segmented into in-vitro and in-vivo. The monoclonal antibodies market, by indication, is further segmented as cancer, autoimmune diseases, infectious diseases, inflammatory diseases, microbial diseases, and others. By application, the market is subsegmented as therapeutic applications, diagnostic applications, and research applications. Furthermore, based on end-user, the market is segmented into hospitals, others, and research institutes..

Monoclonal antibodies Market - by Geography

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • Italy
    • UK
    • Spain
    • Rest of Europe
  • Asia Pacific (APAC)
    • China
    • India
    • South Korea
    • Japan
    • Australia
    • Rest of APAC
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Rest of MEA
  • South and Central America (SCAM)
    • Brazil
    • Argentina
    • Rest of SCAM

Company Profiles

  • Novartis AG
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Amgen, Inc
  • Daiichi Sankyo Company, Limited
  • F. Hoffmann-La Roche AG
  • AstraZeneca
  • Elli Lily and Company
  • Bayer AG
  • Bristol-Myers Squibb Company

Frequently Asked Questions

What is meant by the monoclonal antibodies market?
Food and Drug Administration (FDA) defines monoclonal antibodies as immunoglobulin molecules that are secreted from a population of identical cells. They are homogenous in structure and binding specificity. These are used as multifunctional components for the immune system. They facilitate numerous cellular and humoral reactions to a variety of antigens, which include host and foreign substances.
What are the driving factors for the monoclonal antibodies market across the globe?
Significant rise in the cancer and chronic diseases is one of the most significant factors responsible for the overall market growth.
Which segment led the monoclonal antibodies market?
Based on source, human segment took the forefront lead in the worldwide market by accounting largest share in 2020 and is expected to continue to do so till the forecast period.
Which production method segment held the largest revenue (US$ Mn) in the monoclonal antibodies market?
The in vitro segment dominated the global monoclonal antibodies market and accounted for the largest revenue of 75,044.50 Mn in 2021.
Who are the key players in the monoclonal antibodies market?
Novartis AG, Pfizer, Inc., GlaxoSmithKline Plc, Amgen, Inc., Daiichi Sankyo Company, Limited, F.Hoffmann-La Roche AG, AstraZeneca, Elli Lilly and Company, Bayer AG, Bristol-Myers Squibb Company are among the leading companies operating in the global monoclonal antibodies market
What is the regional market scenario of the monoclonal antibodies market?
Global monoclonal antibodies market is segmented by region into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America. In North America, the U.S. is the largest market for monoclonal antibodies market. The US is estimated to hold the largest share in the monoclonal antibodies market during the forecast period. The presence of top players and favorable regulations related to product approvals coupled with commercializing new products are the contributing factors for the regional growth. Additionally, the increasing number of R&D activities is the key factor responsible for the Asia-Pacific regional growth for monoclonal antibodies accounting fastest growth of the region during the coming years.

1. Introduction

1.1 Scope of the Study

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 Global Monoclonal Antibodies (mAbs) Market – By Source

1.3.2 Global Monoclonal Antibodies (mAbs) Market – By Production Method

1.3.3 Global Monoclonal Antibodies (mAbs) Market – By Indication

1.3.4 Global Monoclonal Antibodies (mAbs) Market – By Application

1.3.5 Global Monoclonal Antibodies (mAbs) Market – By End-User

1.3.6 Global Monoclonal Antibodies (mAbs) Market – By Geography

2. Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. Monoclonal Antibodies (mAbs) Market – Market Landscape

4.1 Overview

4.2 PEST Analysis

4.2.1 North America PEST Analysis

4.2.2 Europe PEST Analysis

4.2.3 Asia Pacific PEST Analysis

4.2.4 Middle East And Africa PEST Analysis

4.2.5 South And Central America PEST Analysis

4.3 Experts Opinion

5. Monoclonal Antibodies (mAbs) Market – Key Market Dynamics

5.1 Market Drivers

5.1.1 Rising Prevalence of Cancer and Other Chronic Diseases

5.1.2 mABs Uptake Proves to be Effective During Pandemic Outbreak

5.2 Market Restraints

5.2.1 Low Awareness, Accessibility, and High Cost

5.3 Market Opportunities

5.3.1 Cost-effective Advanced Technology for Developing mABs Presents Billion-Dollar Opportunity

5.4 Future Trends

5.4.1 Strategic Research Collaborations

5.5 Impact Analysis

6. Monoclonal Antibodies (mAbs) Market– Global Analysis

6.1 Global Monoclonal Antibodies (mAbs) Market Revenue Forecast and Analysis

6.2 Global Monoclonal Antibodies (mAbs) Market, By Geography - Forecast and Analysis

6.3 Market Positioning of Key Players

7. Global Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028– by Source

7.1 Overview

7.2 Global Monoclonal Antibodies (mAbs) Market, By Source, 2021 & 2028 (%)

7.3 Murine

7.3.1 Overview

7.3.2 Murine: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

7.4 Chimeric

7.4.1 Overview

7.4.2 Chimeric: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

7.5 Humanized

7.5.1 Overview

7.5.2 Humanized: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

7.6 Human

7.6.1 Overview

7.6.2 Human: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

8. Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 – Production Method

8.1 Overview

8.2 Global Monoclonal Antibodies (mAbs) Market Share by Production Method Segment - 2021 & 2028 (%)

8.3 In-Vivo

8.3.1 Overview

8.3.2 In-Vivo: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

8.4 In-Vitro

8.4.1 Overview

8.4.2 In-Vitro: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

9. Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 – Indication

9.1 Overview

9.2 Global Monoclonal Antibodies (mAbs) Market Share by Indication Segment - 2021 & 2028 (%)

9.3 Cancer

9.3.1 Overview

9.3.2 Cancer: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

9.4 Autoimmune Diseases

9.4.1 Overview

9.4.2 Autoimmune Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

9.5 Inflammatory Diseases

9.5.1 Overview

9.5.2 Inflammatory Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

9.6 Infectious Diseases

9.6.1 Overview

9.6.2 Infectious Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

9.7 Microbial Diseases

9.7.1 Overview

9.7.2 Microbial Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

9.8 Others

9.8.1 Overview

9.8.2 Others: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

10. Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 – Application

10.1 Overview

10.2 Global Monoclonal Antibodies (mAbs) Market Share by Application Segment - 2021 & 2028 (%)

10.3 Diagnostic Applications

10.3.1 Overview

10.3.2 Diagnostic Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

10.4 Therapeutic Applications

10.4.1 Overview

10.4.2 Therapeutic Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

10.5 Research Applications

10.5.1 Overview

10.5.2 Research Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

11. Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 – End-User

11.1 Overview

11.2 Global Monoclonal Antibodies (mAbs) Market Share by End-User Segment - 2021 & 2028 (%)

11.3 Hospitals

11.3.1 Overview

11.3.2 Hospitals: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

11.4 Research Institutes

11.4.1 Overview

11.4.2 Research Institutes: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

11.5 Others

11.5.1 Overview

11.5.2 Others: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

12. Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 – Geographical Analysis

12.1 North America: Monoclonal Antibodies (mAbs) Market

12.1.1 Overview

12.1.2 North America: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (US$ Million)

12.1.3 North America: Monoclonal Antibodies (mAbs) Market, by Source, 2019–2028 (US$ Million)

12.1.4 North America: Monoclonal Antibodies (mAbs) Market, by Production, 2019–2028 (US$ Million)

12.1.5 North America: Monoclonal Antibodies (mAbs) Market, by Indication, 2019–2028 (US$ Million)

12.1.6 North America: Monoclonal Antibodies (mAbs) Market, by Application, 2019–2028 (US$ Million)

12.1.7 North America: Monoclonal Antibodies (mAbs) Market, by End-User, 2019–2028 (US$ Million)

12.1.8 North America: Monoclonal Antibodies (mAbs) Market, by Country, 2021 & 2028 (%)

12.1.8.1 US: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (US$ Million)

12.1.8.1.1 Overview

12.1.8.1.2 US: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (US$ Million)

12.1.8.1.3 US: Monoclonal Antibodies (mAbs) Market, by Source, 2019–2028 (US$ Million)

12.1.8.1.4 US: Monoclonal Antibodies (mAbs) Market, by Production, 2019–2028 (US$ Million)

12.1.8.1.5 US: Monoclonal Antibodies (mAbs) Market, by Indication, 2019–2028 (US$ Million)

12.1.8.1.6 US: Monoclonal Antibodies (mAbs) Market, by Application, 2019–2028 (US$ Million)

12.1.8.1.7 US: Monoclonal Antibodies (mAbs) Market, by End-User, 2019–2028 (US$ Million)

12.1.8.2 Canada: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (US$ Million)

12.1.8.2.1 Overview

12.1.8.2.2 Canada: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (US$ Million)

12.1.8.2.3 Canada: Monoclonal Antibodies (mAbs) Market, by Source, 2019–2028 (US$ Million)

12.1.8.2.4 Canada: Monoclonal Antibodies (mAbs) Market, by Production, 2019–2028 (US$ Million)

12.1.8.2.5 Canada: Monoclonal Antibodies (mAbs) Market, by Indication, 2019–2028 (US$ Million)

12.1.8.2.6 Canada: Monoclonal Antibodies (mAbs) Market, by Application, 2019–2028 (US$ Million)

12.1.8.2.7 Canada: Monoclonal Antibodies (mAbs) Market, by End-User, 2019–2028 (US$ Million)

12.1.8.3 Mexico: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (US$ Million)

12.1.8.3.1 Overview

12.1.8.3.2 Mexico: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (US$ Million)

12.1.8.3.3 Mexico: Monoclonal Antibodies (mAbs) Market, by Source, 2019–2028 (US$ Million)

12.1.8.3.4 Mexico: Monoclonal Antibodies (mAbs) Market, by Production, 2019–2028 (US$ Million)

12.1.8.3.5 Mexico: Monoclonal Antibodies (mAbs) Market, by Indication, 2019–2028 (US$ Million)

12.1.8.3.6 Mexico: Monoclonal Antibodies (mAbs) Market, by Application, 2019–2028 (US$ Million)

12.1.8.3.7 Mexico: Monoclonal Antibodies (mAbs) Market, by End-User, 2019–2028 (US$ Million)

12.2 Europe: Monoclonal Antibodies (mAbs) Market

12.2.1 Overview

12.2.2 Europe: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Mn)

12.2.3 Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Mn)

12.2.4 Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Mn)

12.2.5 Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication (US$ Mn)

12.2.6 Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application (US$ Mn)

12.2.7 Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, by End User (US$ Mn)

12.2.8 Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Country (%)

12.2.8.1 Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Mn)

12.2.8.1.1 Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Mn)

12.2.8.1.2 Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Mn)

12.2.8.1.3 Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Mn)

12.2.8.1.4 Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication (US$ Mn)

12.2.8.1.5 Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application (US$ Mn)

12.2.8.1.6 Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Product (US$ Mn)

12.2.8.1.7 Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, by End User (US$ Mn)

12.2.8.2 UK Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Mn)

12.2.8.2.1 UK Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Mn)

12.2.8.2.2 UK Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Mn)

12.2.8.2.3 UK Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Mn)

12.2.8.2.4 UK Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication (US$ Mn)

12.2.8.2.5 UK Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application (US$ Mn)

12.2.8.2.6 UK Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, by End User US$ Mn)

12.2.8.3 France Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Mn)

12.2.8.3.1 France Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Mn)

12.2.8.3.2 France Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Mn)

12.2.8.3.3 France Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Mn)

12.2.8.3.4 France Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication (US$ Mn)

12.2.8.3.5 France Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application (US$ Mn)

12.2.8.3.6 France Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, by End User (US$ Mn)

12.2.8.4 Italy Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Mn)

12.2.8.4.1 Italy Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Mn)

12.2.8.4.2 Italy Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Mn)

12.2.8.4.3 Italy Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Mn)

12.2.8.4.4 Italy Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication (US$ Mn)

12.2.8.4.5 Italy Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application (US$ Mn)

12.2.8.4.6 Italy Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, by End User (US$ Mn)

12.2.8.5 Spain Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Mn)

12.2.8.5.1 Spain Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Mn)

12.2.8.5.2 Spain Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Mn)

12.2.8.5.3 Spain Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Mn)

12.2.8.5.4 Spain Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication (US$ Mn)

12.2.8.5.5 Spain Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application (US$ Mn)

12.2.8.5.6 Spain Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, by End User (US$ Mn)

12.2.8.6 Rest of Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Mn)

12.2.8.6.1 Rest of Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Mn)

12.2.8.6.2 Rest of Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source(US$ Mn)

12.2.8.6.3 Rest of Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Mn)

12.2.8.6.4 Rest of Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication(US$ Mn)

12.2.8.6.5 Rest of Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application(US$ Mn)

12.2.8.6.6 Rest of Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, by End User (US$ Mn)

12.3 Asia Pacific Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028

12.3.1 Overview

12.3.2 Asia Pacific: Monoclonal Antibodies (mAbs) Market - Revenue and Forecast to 2028 (USD Million)

12.3.3 Asia Pacific: Monoclonal Antibodies (mAbs) Market, by Source, 2019–2028 (USD Million)

12.3.4 Asia Pacific: Monoclonal Antibodies (mAbs) Market, by Production Method, 2019–2028 (USD Million)

12.3.5 Asia Pacific: Monoclonal Antibodies (mAbs) Market, by Indication, 2019–2028 (USD Million)

12.3.6 Asia Pacific: Monoclonal Antibodies (mAbs) Market, by Application, 2019–2028 (USD Million)

12.3.7 Asia Pacific: Monoclonal Antibodies (mAbs) Market, By End User, 2019–2028 (USD Million)

12.3.8 Asia Pacific: Monoclonal Antibodies (mAbs) Market, by Country, 2021 & 2028 (%)

12.3.8.1 China: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (USD Million)

12.3.8.1.1 China: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (USD Million)

12.3.8.1.2 China: Monoclonal Antibodies (mAbs) Market, by Source, 2019–2028 (USD Million)

12.3.8.1.3 China: Monoclonal Antibodies (mAbs) Market, by Production Method, 2019–2028 (USD Million)

12.3.8.1.4 China: Monoclonal Antibodies (mAbs) Market, by Indication, 2019–2028 (USD Million)

12.3.8.1.5 China: Monoclonal Antibodies (mAbs) Market, by Application, 2019–2028 (USD Million)

12.3.8.1.6 China: Monoclonal Antibodies (mAbs) Market, by Product, 2019–2028 (USD Million)

12.3.8.1.7 China: Monoclonal Antibodies (mAbs) Market, By End User, 2019–2028 (USD Million)

12.3.8.2 Japan: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (USD Million)

12.3.8.2.1 Japan: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (USD Million)

12.3.8.2.2 Japan: Monoclonal Antibodies (mAbs) Market, by Source, 2019–2028 (USD Million)

12.3.8.2.3 Japan: Monoclonal Antibodies (mAbs) Market, by Product, 2019–2028 (USD Million)

12.3.8.2.4 Japan: Monoclonal Antibodies (mAbs) Market, by Production Method, 2019–2028 (USD Million)

12.3.8.2.5 Japan: Monoclonal Antibodies (mAbs) Market, by Indication, 2019–2028 (USD Million)

12.3.8.2.6 Japan: Monoclonal Antibodies (mAbs) Market, by Application, 2019–2028 (USD Million)

12.3.8.2.7 Japan: Monoclonal Antibodies (mAbs) Market, By End User, 2019–2028 (USD Million)

12.3.8.3 India: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (USD Million)

12.3.8.3.1 India: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (USD Million)

12.3.8.3.2 India: Monoclonal Antibodies (mAbs) Market, by Source, 2019–2028 (USD Million)

12.3.8.3.3 India: Monoclonal Antibodies (mAbs) Market, by Production Method, 2019–2028 (USD Million)

12.3.8.3.4 India: Monoclonal Antibodies (mAbs) Market, by Indication, 2019–2028 (USD Million)

12.3.8.3.5 India: Monoclonal Antibodies (mAbs) Market, by Application, 2019–2028 (USD Million)

12.3.8.3.6 India: Monoclonal Antibodies (mAbs) Market, By End User, 2019–2028 (USD Million)

12.3.8.4 South Korea: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (USD Million)

12.3.8.4.1 South Korea: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (USD Million)

12.3.8.4.2 South Korea: Monoclonal Antibodies (mAbs) Market, by Source, 2019–2028 (USD Million)

12.3.8.4.3 South Korea: Monoclonal Antibodies (mAbs) Market, by Production Method, 2019–2028 (USD Million)

12.3.8.4.4 South Korea: Monoclonal Antibodies (mAbs) Market, by Indication, 2019–2028 (USD Million)

12.3.8.4.5 South Korea: Monoclonal Antibodies (mAbs) Market, By End User, 2019–2028 (USD Million)

12.3.8.5 Australia: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (USD Million)

12.3.8.5.1 Australia: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (USD Million)

12.3.8.5.2 Australia: Monoclonal Antibodies (mAbs) Market, by Source, 2019–2028 (USD Million)

12.3.8.5.3 Australia: Monoclonal Antibodies (mAbs) Market, By Production Method, 2019–2028 (USD Million)

12.3.8.5.4 Australia: Monoclonal Antibodies (mAbs) Market, By Indication, 2019–2028 (USD Million)

12.3.8.5.5 Australia: Monoclonal Antibodies (mAbs) Market, By Application, 2019–2028 (USD Million)

12.3.8.5.6 Australia: Monoclonal Antibodies (mAbs) Market, By End User, 2019–2028 (USD Million)

12.3.8.6 Rest of Asia Pacific: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (USD Million)

12.3.8.6.1 Rest of Asia Pacific: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (USD Million)

12.3.8.6.2 Rest of Asia Pacific: Monoclonal Antibodies (mAbs) Market, by Source, 2019–2028 (USD Million)

12.3.8.6.3 Rest of Asia Pacific: Monoclonal Antibodies (mAbs) Market, by Production Method, 2019–2028 (USD Million)

12.3.8.6.4 Rest of Asia Pacific: Monoclonal Antibodies (mAbs) Market, by Indication, 2019–2028 (USD Million)

12.3.8.6.5 Rest of Asia Pacific: Monoclonal Antibodies (mAbs) Market, by Application, 2019–2028 (USD Million)

12.3.8.6.6 Rest of Asia Pacific: Monoclonal Antibodies (mAbs) Market, By End User, 2019–2028 (USD Million)

12.4 Middle East & Africa Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028

12.4.1 Overview

12.4.2 Middle East & Africa Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

12.4.3 Middle East & Africa: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)

12.4.4 Middle East & Africa: Metabolomics Market Revenue and Forecasts to 2028, By Production (US$ Million)

12.4.5 Middle East & Africa: Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

12.4.6 Middle East & Africa: Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (US$ Million)

12.4.7 Middle East & Africa: Monoclonal Antibodies (mAbs) Market, by End-User – Revenue and Forecast to 2028 (US$ Million)

12.4.8 Middle East & Africa Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Country (%)

12.4.8.1 UAE: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

12.4.8.1.1 Overview

12.4.8.1.2 UAE: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

12.4.8.1.3 UAE: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)

12.4.8.1.4 UAE: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028, By Production (US$ Million)

12.4.8.1.5 UAE: Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

12.4.8.1.6 UAE: Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (US$ Million)

12.4.8.1.7 UAE: Monoclonal Antibodies (mAbs) Market, by End-User – Revenue and Forecast to 2028 (US$ Million)

12.4.8.2 Saudi Arabia: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

12.4.8.2.1 Overview

12.4.8.2.2 Saudi Arabia: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

12.4.8.2.3 Saudi Arabia: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)

12.4.8.2.4 Saudi Arabia: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028, By Production (US$ Million)

12.4.8.2.5 Saudi Arabia: Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

12.4.8.2.6 Saudi Arabia: Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (US$ Million)

12.4.8.2.7 Saudi Arabia: Monoclonal Antibodies (mAbs) Market, by End-User – Revenue and Forecast to 2028 (US$ Million)

12.4.8.3 South Africa: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

12.4.8.3.1 Overview

12.4.8.3.2 South Africa Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

12.4.8.3.3 South Africa: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)

12.4.8.3.4 South Africa: Metabolomics Market Revenue and Forecasts To 2028, By Production (US$ Million)

12.4.8.3.5 South Africa: Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

12.4.8.3.6 South Africa: Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (US$ Million)

12.4.8.3.7 South Africa: Monoclonal Antibodies (mAbs) Market, by End-User – Revenue and Forecast to 2028 (US$ Million)

12.5 South And Central America Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028

12.5.1 Overview

12.5.2 South and Central America Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

12.5.3 South and Central America Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)

12.5.4 South and Central America: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production (US$ Million)

12.5.5 South and Central America: Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

12.5.6 South and Central America: Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (US$ Million)

12.5.7 South and Central America: Monoclonal Antibodies (mAbs) Market, by End-User – Revenue and Forecast to 2028 (US$ Million)

12.5.8 South and Central America Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Country (%)

12.5.8.1 Argentina Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

12.5.8.1.1 Overview

12.5.8.1.2 Argentina Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

12.5.8.1.3 Argentina: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)

12.5.8.1.4 Argentina: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028, By Production (US$ Million)

12.5.8.1.5 Argentina: Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

12.5.8.1.6 Argentina: Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (US$ Million)

12.5.8.1.7 Argentina: Monoclonal Antibodies (mAbs) Market, by End-User – Revenue and Forecast to 2028 (US$ Million)

12.5.8.2 Brazil: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

12.5.8.2.1 Overview

12.5.8.2.2 Brazil: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

12.5.8.2.3 Brazil: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)

12.5.8.2.4 Brazil: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028, By Production (US$ Million)

12.5.8.2.5 Brazil: Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

12.5.8.2.6 Brazil: Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (US$ Million)

12.5.8.2.7 Brazil: Monoclonal Antibodies (mAbs) Market, by End-User – Revenue and Forecast to 2028 (US$ Million)

12.5.8.3 Rest of South and Central America: Monoclonal Antibodies (mAbs) Market– Revenue and Forecast to 2028 (USD Mn)

12.5.8.3.1 Overview

12.5.8.3.2 Rest of South and Central America: Monoclonal Antibodies (mAbs) Market– Revenue and Forecast to 2028 (USD Mn)

12.5.8.3.3 Rest of South & Central America: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)

12.5.8.3.4 Rest of South & Central America: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028, By Production (US$ Million)

12.5.8.3.5 Rest of South and Central America: Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

12.5.8.3.6 Rest of South and Central America: Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (US$ Million)

12.5.8.3.7 Rest of South and Central America: Monoclonal Antibodies (mAbs) Market, by End-User – Revenue and Forecast to 2028 (US$ Million)

13. Impact Of COVID-19 Pandemic on Monoclonal Antibodies (mAbs) Market

13.1 North America: Impact Assessment of COVID-19 Pandemic

13.2 Europe: Impact Assessment of COVID-19 Pandemic

13.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic

13.4 Middle East and Africa: Impact Assessment of COVID-19 Pandemic

13.5 South and Central America: Impact Assessment of COVID-19 Pandemic

14. Monoclonal Antibodies (mAbs) Market–Industry Landscape

14.1 Overview

14.2 Growth Strategies Done by the Companies in the Market, (%)

14.3 Organic Developments

14.3.1 Overview

14.4 Inorganic Developments

14.4.1 Overview

15. Company Profiles

15.1 Novartis AG

15.1.1 Key Facts

15.1.2 Business Description

15.1.3 Products and Services

15.1.4 Financial Overview

15.1.5 SWOT Analysis

15.1.6 Key Developments

15.2 Pfizer Inc.

15.2.1 Key Facts

15.2.2 Business Description

15.2.3 Products and Services

15.2.4 Financial Overview

15.2.5 SWOT Analysis

15.2.6 Key Developments

15.3 GlaxoSmithKline plc.

15.3.1 Key Facts

15.3.2 Business Description

15.3.3 Products and Services

15.3.4 Financial Overview

15.3.5 SWOT Analysis

15.3.6 Key Developments

15.4 Amgen Inc.

15.4.1 Key Facts

15.4.2 Business Description

15.4.3 Products and Services

15.4.4 Financial Overview

15.4.5 SWOT Analysis

15.4.6 Key Developments

15.5 DAIICHI SANKYO COMPANY LIMITED

15.5.1 Key Facts

15.5.2 Business Description

15.5.3 Products and Services

15.5.4 Financial Overview

15.5.5 SWOT Analysis

15.5.6 Key Developments

15.6 F. HOFFMANN-LA ROCHE LTD.

15.6.1 Key Facts

15.6.2 Business Description

15.6.3 Products and Services

15.6.4 Financial Overview

15.6.5 SWOT Analysis

15.6.6 Key Developments

15.7 AstraZeneca

15.7.1 Key Facts

15.7.2 Business Description

15.7.3 Products and Services

15.7.4 Financial Overview

15.7.5 SWOT Analysis

15.7.6 Key Developments

15.8 Eli Lilly and Company.

15.8.1 Key Facts

15.8.2 Business Description

15.8.3 Products and Services

15.8.4 Financial Overview

15.8.5 SWOT Analysis

15.8.6 Key Developments

15.9 Bayer AG

15.9.1 Key Facts

15.9.2 Business Description

15.9.3 Products and Services

15.9.4 Financial Overview

15.9.5 SWOT Analysis

15.9.6 Key Developments

15.10 Bristol-Myers Squibb Company

15.10.1 Key Facts

15.10.2 Business Description

15.10.3 Products and Services

15.10.4 Financial Overview

15.10.5 SWOT Analysis

15.10.6 Key Developments

16. Appendix

16.1 About The Insight Partners

16.2 Glossary of Terms

LIST OF TABLES

Table 1. North America Monoclonal Antibodies (mAbs) Market, by Source – Revenue and Forecast to 2028 (US$ Million)

Table 2. North America Monoclonal Antibodies (mAbs) Market, by Production– Revenue and Forecast to 2028 (USD Million)

Table 3. North America Monoclonal Antibodies (mAbs) Market, by Indication– Revenue and Forecast to 2028 (US$ Million)

Table 4. North America Monoclonal Antibodies (mAbs) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

Table 5. North America Monoclonal Antibodies (mAbs) Market, by End-User– Revenue and Forecast to 2028 (US$ Million)

Table 6. US Monoclonal Antibodies (mAbs) Market, by Source – Revenue and Forecast to 2028 (US$ Million)

Table 7. US Monoclonal Antibodies (mAbs) Market, by Production– Revenue and Forecast to 2028 (US$ Million)

Table 8. US Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

Table 9. US Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 10. US Monoclonal Antibodies (mAbs) Market, by End-User – Revenue and Forecast to 2028 (US$ Million)

Table 11. Canada: Monoclonal Antibodies (mAbs) Market, by Source – Revenue and Forecast to 2028 (US$ Million)

Table 12. Canada Monoclonal Antibodies (mAbs) Market, by Production– Revenue and Forecast to 2028 (US$ Million)

Table 13. Canada Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

Table 14. Canada Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 15. Canada Monoclonal Antibodies (mAbs) Market, by End-User – Revenue and Forecast to 2028 (US$ Million)

Table 16. Mexico: Monoclonal Antibodies (mAbs) Market, by Source – Revenue and Forecast to 2028 (US$ Million)

Table 17. Mexico Monoclonal Antibodies (mAbs) Market, by Production– Revenue and Forecast to 2028 (US$ Million)

Table 18. Mexico Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

Table 19. Mexico Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 20. Mexico Monoclonal Antibodies (mAbs) Market, by End-User – Revenue and Forecast to 2028 (US$ Million)

Table 21. Europe and Middle East and Africa Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Mn).

Table 22. Europe and Middle East and Africa Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Mn).

Table 23. Europe and Middle East and Africa Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication (US$ Mn).

Table 24. Europe and Middle East and Africa Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application (US$ Mn).

Table 25. Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, by End User (US$ Mn)

Table 26. Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Mn)

Table 27. Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Mn)

Table 28. Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication (US$ Mn)

Table 29. Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application (US$ Mn)

Table 30. Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Product US$ Mn)

Table 31. Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, by End User (US$ Mn)

Table 32. UK Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Mn)

Table 33. UK Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Mn)

Table 34. UK Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication (US$ Mn)

Table 35. UK Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application (US$ Mn)

Table 36. UK Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, by End User US$ Mn)

Table 37. France Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Mn)

Table 38. France Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Mn)

Table 39. France Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication (US$ Mn)

Table 40. France Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application (US$ Mn)

Table 41. France Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, by End User (US$ Mn)

Table 42. Italy Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Mn)

Table 43. Italy Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Mn)

Table 44. Italy Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication (US$ Mn)

Table 45. Italy Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application (US$ Mn)

Table 46. Italy Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, by End User (US$ Mn)

Table 47. Spain Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Mn)

Table 48. Spain Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Mn)

Table 49. Spain Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication (US$ Mn)

Table 50. Spain Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application (US$ Mn)

Table 51. Spain Monoclonal Antibodies (mAbs) Market, by End User – Revenue and Forecast to 2028 by End User (USD Million)

Table 52. Rest of Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Mn)

Table 53. Rest of Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Mn)

Table 54. Rest of Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication (US$ Mn)

Table 55. Rest of Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application (US$ Mn)

Table 56. Rest of Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, by End User (US$ Mn)

Table 57. Asia Pacific Monoclonal Antibodies (mAbs) Market, by Source – Revenue and Forecast to 2028 (USD Million)

Table 58. Asia Pacific Monoclonal Antibodies (mAbs) Market, by Production Method – Revenue and Forecast to 2028 (USD Million)

Table 59. Asia Pacific Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (USD Million)

Table 60. Asia Pacific Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (USD Million)

Table 61. Asia Pacific Monoclonal Antibodies (mAbs) Market, By End User – Revenue and Forecast to 2028 (USD Million)

Table 62. China Monoclonal Antibodies (mAbs) Market, by Source – Revenue and Forecast to 2028 (USD Million)

Table 63. China Monoclonal Antibodies (mAbs) Market, by Production Method – Revenue and Forecast to 2028 (USD Million)

Table 64. China Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (USD Million)

Table 65. China Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (USD Million)

Table 66. China Monoclonal Antibodies (mAbs) Market, by Product – Revenue and Forecast to 2028 (USD Million)

Table 67. China Monoclonal Antibodies (mAbs) Market, By End User – Revenue and Forecast to 2028 (USD Million)

Table 68. Japan Monoclonal Antibodies (mAbs) Market, by Source – Revenue and Forecast to 2028 (USD Million)

Table 69. Japan Monoclonal Antibodies (mAbs) Market, by Product – Revenue and Forecast to 2028 (USD Million)

Table 70. Japan Monoclonal Antibodies (mAbs) Market, by Production Method – Revenue and Forecast to 2028 (USD Million)

Table 71. Japan Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (USD Million)

Table 72. Japan Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (USD Million)

Table 73. Japan Monoclonal Antibodies (mAbs) Market, By End User – Revenue and Forecast to 2028 (USD Million)

Table 74. India Monoclonal Antibodies (mAbs) Market, by Source – Revenue and Forecast to 2028 (USD Million)

Table 75. India Monoclonal Antibodies (mAbs) Market, by Production Method – Revenue and Forecast to 2028 (USD Million)

Table 76. India Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (USD Million)

Table 77. India Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (USD Million)

Table 78. India Monoclonal Antibodies (mAbs) Market, By End User – Revenue and Forecast to 2028 (USD Million)

Table 79. South Korea Monoclonal Antibodies (mAbs) Market, by Product – Revenue and Forecast to 2028 (USD Million)

Table 80. South Korea Monoclonal Antibodies (mAbs) Market, by Production Method – Revenue and Forecast to 2028 (USD Million)

Table 81. South Korea Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (USD Million)

Table 82. South Korea Monoclonal Antibodies (mAbs) Market, By End User – Revenue and Forecast to 2028 (USD Million)

Table 83. Australia Monoclonal Antibodies (mAbs) Market, by Source – Revenue and Forecast to 2028 (USD Million)

Table 84. Australia Monoclonal Antibodies (mAbs) Market, By Production Method – Revenue and Forecast to 2028 (USD Million)

Table 85. Australia Monoclonal Antibodies (mAbs) Market, By Indication – Revenue and Forecast to 2028 (USD Million)

Table 86. Australia Monoclonal Antibodies (mAbs) Market, By Application – Revenue and Forecast to 2028 (USD Million)

Table 87. Australia Monoclonal Antibodies (mAbs) Market, By End User – Revenue and Forecast to 2028 (USD Million)

Table 88. Rest of Asia Pacific Monoclonal Antibodies (mAbs) Market, by Source – Revenue and Forecast to 2028 (USD Million)

Table 89. Rest of Asia Pacific Monoclonal Antibodies (mAbs) Market, by Production Method – Revenue and Forecast to 2028 (USD Million)

Table 90. Rest of Asia Pacific Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (USD Million)

Table 91. Rest of Asia Pacific Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (USD Million)

Table 92. Rest of Asia Pacific Monoclonal Antibodies (mAbs) Market, By End User – Revenue and Forecast to 2028 (USD Million)

Table 93. Middle East & Africa: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)

Table 94. Middle East & Africa: Metabolomics Market Revenue and Forecasts to 2028, By Production (US$ Million)

Table 95. Middle East & Africa: Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

Table 96. Middle East & Africa: Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 97. Middle East & Africa: Monoclonal Antibodies (mAbs) Market, by End-User – Revenue and Forecast to 2028 (US$ Million)

Table 98. UAE: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)

Table 99. UAE: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production (US$ Million)

Table 100. UAE: Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

Table 101. UAE: Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 102. UAE: Monoclonal Antibodies (mAbs) Market, by End-User – Revenue and Forecast to 2028 (US$ Million)

Table 103. Saudi Arabia: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)

Table 104. Saudi Arabia: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production (US$ Million)

Table 105. Saudi Arabia: Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

Table 106. Saudi Arabia: Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 107. Saudi Arabia: Monoclonal Antibodies (mAbs) Market, by End-User – Revenue and Forecast to 2028 (US$ Million)

Table 108. South Africa Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)

Table 109. South Africa: Metabolomics Market Revenue and Forecasts to 2028, By Production (US$ Million)

Table 110. South Africa: Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

Table 111. South Africa: Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 112. South Africa: Monoclonal Antibodies (mAbs) Market, by End-User – Revenue and Forecast to 2028 (US$ Million)

Table 113. South and Central America Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)

Table 114. South and Central America: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production (US$ Million)

Table 115. South and Central America: Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

Table 116. South and Central America: Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 117. South and Central America: Monoclonal Antibodies (mAbs) Market, by End-User – Revenue and Forecast to 2028 (US$ Million)

Table 118. Argentina: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)

Table 119. Argentina: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production (US$ Million)

Table 120. Argentina: Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

Table 121. Argentina: Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 122. Argentina: Monoclonal Antibodies (mAbs) Market, by End-User – Revenue and Forecast to 2028 (US$ Million)

Table 123. Brazil: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)

Table 124. Brazil: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production (US$ Million)

Table 125. Brazil: Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

Table 126. Brazil: Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 127. Brazil: Monoclonal Antibodies (mAbs) Market, by End-User – Revenue and Forecast to 2028 (US$ Million)

Table 128. Rest of South & Central America: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)

Table 129. Rest of South & Central America: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production (US$ Million)

Table 130. Rest of South and Central America: Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

Table 131. Rest of South and Central America: Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 132. Rest of South and Central America: Monoclonal Antibodies (mAbs) Market, by End-User – Revenue and Forecast to 2028 (US$ Million)

Table 133. Organic Developments Done by Companies

Table 134. Inorganic Developments Done by Companies

Table 135. Glossary of Terms

LIST OF FIGURES

Figure 1. Monoclonal Antibodies (mAbs) Market Segmentation

Figure 2. Monoclonal Antibodies (mAbs) Market, By Region

Figure 3. Global Monoclonal Antibodies (mAbs) Market Overview

Figure 4. Human Segment Held Largest Share of Type Segment in Monoclonal Antibodies (mAbs) Market

Figure 5. Asia Pacific is Expected to Show Remarkable Growth During the Forecast Period

Figure 6. Monoclonal Antibodies (mAbs) Market, by Geography (US$ Million)

Figure 7. Global Monoclonal Antibodies (mAbs) Market- Leading Country Markets (US$ Million)

Figure 8. Global Monoclonal Antibodies (mAbs) Market, Industry Landscape

Figure 9. North America: PEST Analysis

Figure 10. Europe: PEST Analysis

Figure 11. Asia Pacific: PEST Analysis

Figure 12. Middle East And Africa: PEST Analysis

Figure 13. South And Central America: PEST Analysis

Figure 14. Experts Opinion

Figure 15. Impact Analysis of Drivers and Restraints Pertaining to Monoclonal Antibodies (mAbs) Market

Figure 16. Global Monoclonal Antibodies (mAbs) Market– Revenue Forecast and Analysis – 2021 - 2028

Figure 17. Global Monoclonal Antibodies (mAbs) Market – By Geography Forecast and Analysis – 2021 - 2028

Figure 18. Market Positioning of Key Players in Global Monoclonal Antibodies (mAbs) Market

Figure 19. Global Monoclonal Antibodies (mAbs) Market, by Source, 2021 & 2028 (%)

Figure 20. Murine: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

Figure 21. Chimeric: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

Figure 22. Humanized: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

Figure 23. Human: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

Figure 24. Global Monoclonal Antibodies (mAbs) Market Share by Production Method Segment - 2021 & 2028 (%)

Figure 25. In-Vivo: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 26. In-Vitro: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 27. Global Monoclonal Antibodies (mAbs) Market Share by Indication Segment - 2021 & 2028 (%)

Figure 28. Cancer: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 29. Autoimmune Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 30. Inflammatory Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 31. Infectious Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 32. Microbial Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 33. Others: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 34. Global Monoclonal Antibodies (mAbs) Market Share by Application Segment - 2021 & 2028 (%)

Figure 35. Diagnostic Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 36. Therapeutic Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 37. Research Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 38. Global Monoclonal Antibodies (mAbs) Market Share by End-User Segment - 2021 & 2028 (%)

Figure 39. Hospitals: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 40. Research Institutes: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 41. Others: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 42. North America: Monoclonal Antibodies (mAbs) Market, by Key Country – Revenue (2021) (US$ Million)

Figure 43. North America Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

Figure 44. North America: Monoclonal Antibodies (mAbs) Market, by Country, 2021 & 2028 (%)

Figure 45. US: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (US$ Million)

Figure 46. Canada: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (US$ Million)

Figure 47. Mexico: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (US$ Million)

Figure 48. Europe: Monoclonal Antibodies (mAbs) Market Revenue Overview, by Country, 2021 (US$ MN)

Figure 49. Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Mn)

Figure 50. Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Country (%)

Figure 51. Asia Pacific: Monoclonal Antibodies (mAbs) Market, by Key Country – Revenue (2021) (USD Million)

Figure 52. Asia Pacific Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (USD Million)

Figure 53. Middle East & Africa Monoclonal Antibodies (mAbs) Market Revenue Overview, by Country, 2021 (US$ Million)

Figure 54. Middle East & Africa Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

Figure 55. Middle East & Africa Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Country (%)

Figure 56. UAE: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

Figure 57. Saudi Arabia: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

Figure 58. South Africa: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

Figure 59. South and Central America Monoclonal Antibodies (mAbs) Market Revenue Overview, by Country, 2021 (US$ Million)

Figure 60. South and Central America Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

Figure 61. South and Central America Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Country (%)

Figure 62. Argentina Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

Figure 63. Brazil: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

Figure 64. Rest of South and Central America: Monoclonal Antibodies (mAbs) Market– Revenue and Forecast to 2028 (USD Mn)

Figure 65. Impact of COVID-19 Pandemic in North American Country Markets

Figure 66. Impact of COVID-19 Pandemic in European Country Markets

Figure 67. Impact of COVID-19 Pandemic in Asia Pacific Country Markets

Figure 68. Impact of COVID-19 Pandemic in Middle East and Africa Country Markets

Figure 69. Impact Of COVID-19 Pandemic in South and Central America Africa Country Markets

Figure 70. Growth Strategies Done by the Companies in the Market, (%)

The List of Companies - Monoclonal Antibody Market

  1. Novartis AG
  2. Pfizer Inc.
  3. GlaxoSmithKline plc
  4. Amgen, Inc
  5. Daiichi Sankyo Company, Limited
  6. F. Hoffmann-La Roche AG
  7. AstraZeneca
  8. Elli Lilly and Company
  9. Bayer AG
  10. Bristol-Myers Squibb Company
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the medical laser systems market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the global monoclonal antibodies market, thereby allowing players across the value chain to develop effective long-term strategies
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.
TIPRE00026641
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Get the Latest COVID-19 Analysis on this market

Download PDF Brochure


Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Speak To Analyst
Pricing
  • $3000
  • $4550
  • $6550
  • $8550
    GET FREE SAMPLE PDF

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

    Inquire for Discount
  Share   Share   Share